The Promise and Reality of Pharmacogenetics in Psychiatry

Peter P Zandi, Jennifer T. Judy

Research output: Contribution to journalArticle

Abstract

Existing psychotropic medications for the treatment of mental illnesses, including antidepressants, mood stabilizers, and antipsychotics, are clinically suboptimal. They are effective in only a subset of patients or produce partial responses, and they are often associated with debilitating side effects that discourage adherence. There is growing enthusiasm in the promise of pharmacogenetics to personalize the use of these treatments to maximize their efficacy and tolerability; however, there is still a long way to go before this promise becomes a reality. This article reviews the progress that has been made in research toward understanding how genetic factors influence psychotropic drug responses and the challenges that lie ahead in translating the research findings into clinical practices that yield tangible benefits for patients with mental illnesses.

Original languageEnglish (US)
Pages (from-to)931-974
Number of pages44
JournalClinics in Laboratory Medicine
Volume30
Issue number4
DOIs
StatePublished - Dec 2010

Fingerprint

Pharmacogenetics
Psychiatry
Psychotropic Drugs
Mentally Ill Persons
Research
Antidepressive Agents
Antipsychotic Agents
Therapeutics

Keywords

  • Antidepressants
  • Antipsychotics
  • Efficacy
  • Genome-wide association study
  • Mood stabilizers
  • Pharmacogenetics
  • Pharmacogenomics
  • Side effects

ASJC Scopus subject areas

  • Biochemistry, medical
  • Clinical Biochemistry

Cite this

The Promise and Reality of Pharmacogenetics in Psychiatry. / Zandi, Peter P; Judy, Jennifer T.

In: Clinics in Laboratory Medicine, Vol. 30, No. 4, 12.2010, p. 931-974.

Research output: Contribution to journalArticle

@article{0dbd637f2e01483bb2525424d23d1e2d,
title = "The Promise and Reality of Pharmacogenetics in Psychiatry",
abstract = "Existing psychotropic medications for the treatment of mental illnesses, including antidepressants, mood stabilizers, and antipsychotics, are clinically suboptimal. They are effective in only a subset of patients or produce partial responses, and they are often associated with debilitating side effects that discourage adherence. There is growing enthusiasm in the promise of pharmacogenetics to personalize the use of these treatments to maximize their efficacy and tolerability; however, there is still a long way to go before this promise becomes a reality. This article reviews the progress that has been made in research toward understanding how genetic factors influence psychotropic drug responses and the challenges that lie ahead in translating the research findings into clinical practices that yield tangible benefits for patients with mental illnesses.",
keywords = "Antidepressants, Antipsychotics, Efficacy, Genome-wide association study, Mood stabilizers, Pharmacogenetics, Pharmacogenomics, Side effects",
author = "Zandi, {Peter P} and Judy, {Jennifer T.}",
year = "2010",
month = "12",
doi = "10.1016/j.cll.2010.07.004",
language = "English (US)",
volume = "30",
pages = "931--974",
journal = "Clinics in Laboratory Medicine",
issn = "0272-2712",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - The Promise and Reality of Pharmacogenetics in Psychiatry

AU - Zandi, Peter P

AU - Judy, Jennifer T.

PY - 2010/12

Y1 - 2010/12

N2 - Existing psychotropic medications for the treatment of mental illnesses, including antidepressants, mood stabilizers, and antipsychotics, are clinically suboptimal. They are effective in only a subset of patients or produce partial responses, and they are often associated with debilitating side effects that discourage adherence. There is growing enthusiasm in the promise of pharmacogenetics to personalize the use of these treatments to maximize their efficacy and tolerability; however, there is still a long way to go before this promise becomes a reality. This article reviews the progress that has been made in research toward understanding how genetic factors influence psychotropic drug responses and the challenges that lie ahead in translating the research findings into clinical practices that yield tangible benefits for patients with mental illnesses.

AB - Existing psychotropic medications for the treatment of mental illnesses, including antidepressants, mood stabilizers, and antipsychotics, are clinically suboptimal. They are effective in only a subset of patients or produce partial responses, and they are often associated with debilitating side effects that discourage adherence. There is growing enthusiasm in the promise of pharmacogenetics to personalize the use of these treatments to maximize their efficacy and tolerability; however, there is still a long way to go before this promise becomes a reality. This article reviews the progress that has been made in research toward understanding how genetic factors influence psychotropic drug responses and the challenges that lie ahead in translating the research findings into clinical practices that yield tangible benefits for patients with mental illnesses.

KW - Antidepressants

KW - Antipsychotics

KW - Efficacy

KW - Genome-wide association study

KW - Mood stabilizers

KW - Pharmacogenetics

KW - Pharmacogenomics

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=77956515350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956515350&partnerID=8YFLogxK

U2 - 10.1016/j.cll.2010.07.004

DO - 10.1016/j.cll.2010.07.004

M3 - Article

C2 - 20832660

AN - SCOPUS:77956515350

VL - 30

SP - 931

EP - 974

JO - Clinics in Laboratory Medicine

JF - Clinics in Laboratory Medicine

SN - 0272-2712

IS - 4

ER -